• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Burell Scott R

    1/30/25 4:30:07 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MBOT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Burell Scott R

    (Last) (First) (Middle)
    C/O MICROBOT MEDICAL INC.
    288 GROVE STREET, SUITE 388

    (Street)
    BRAINTREE MA 02184

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Microbot Medical Inc. [ MBOT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/28/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.93 01/28/2025 A 10,000 12/17/2025 01/28/2035 Common Stock, par value $0.01 per share 10,000 $0 10,000 D
    Explanation of Responses:
    /s/ Scott Burell 01/29/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MBOT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MBOT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MBOT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index

      HINGHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it has been selected for inclusion in the preliminary list of additions to the Russell Microcap® Index, as published by FTSE Russell on Friday, May 23, 2025. The newly reconstituted indexes are expected to take effect after U.S. market close on Friday, June 27, 2025, and be part of the 2025 Russell indexes reconstitution when the U.S. market opens on Monday, June 30, 2025. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30, 2025, ranking them by total market capitaliz

      6/5/25 8:30:00 AM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers

      The addition of a seasoned VP of Marketing compliments the recent hiring of the Company's VP of Sales to establish its commercialization readiness infrastructure Positive data from the recently published pivotal study raises confidence that LIBERTY® will be well received in the market HINGHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the addition of two senior officers that round out the Company's U.S. commercial leadership team. Combined with the recent addition of Paul Mullen as Vice President of Sales, the Company is preparing for U.S. commercial launch in advanc

      4/23/25 8:30:00 AM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System

      Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. The study was performed at three leading medical centers in the U.S.; Memorial Sloan Kettering Cancer Center (New York, NY), Baptist Hospital of Miami (Miami, FL) and Brigham and Women's Hospital (Boston, MA). The late-b

      4/9/25 8:30:00 AM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by General Manager, CTO Sharon Simon

      4 - Microbot Medical Inc. (0000883975) (Issuer)

      2/7/25 4:30:14 PM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Diaz-Cartelle Juan

      4 - Microbot Medical Inc. (0000883975) (Issuer)

      2/7/25 4:30:13 PM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Vaknin Rachel

      4 - Microbot Medical Inc. (0000883975) (Issuer)

      2/7/25 4:30:17 PM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MBOT
    SEC Filings

    See more
    • Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Microbot Medical Inc. (0000883975) (Filer)

      6/5/25 8:30:10 AM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Microbot Medical Inc.

      10-Q - Microbot Medical Inc. (0000883975) (Filer)

      5/14/25 4:15:44 PM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Microbot Medical Inc. (0000883975) (Filer)

      4/30/25 5:16:00 PM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MBOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Microbot Medical Inc. (Amendment)

      SC 13G/A - Microbot Medical Inc. (0000883975) (Subject)

      2/14/24 2:49:35 PM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Microbot Medical Inc.

      SC 13G - Microbot Medical Inc. (0000883975) (Subject)

      2/14/23 1:04:05 PM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MBOT
    Leadership Updates

    Live Leadership Updates

    See more
    • Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System

      Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year This Appointment Represents the Company's First Commercial Hire as it Ramps Up Commercial Readiness in Anticipation of FDA Clearance during the Second Quarter of 2025 BRAINTREE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the appointment of Paul Mullen, a seasoned medical device sales expert in the Endovascular space, to the newly created role of Vice President of Sales. Mr. Mullen has an extensive track record in sales, market developm

      3/4/25 8:30:00 AM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®

      BRAINTREE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the appointment of Ms. Michal Ahuvia, to the newly created role of Director of Operations. In this role, Ms. Ahuvia will assume responsibility to ramp-up production and improve production efficiencies as the Company prepares for the planned commercial launch of LIBERTY®, which is anticipated in the second quarter of 2025. Ms. Ahuvia will report to Simon Sharon, the Company's General Manager and Chief Technology Officer, and her addition is expected to play a crucial role in strengthening the Company's manufacturing and op

      1/21/25 8:30:00 AM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities

      BRAINTREE, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced the appointment of Dr. Juan Diaz-Cartelle as its new Chief Medical Officer (CMO), effective December 1, 2023. The hiring of Dr. Diaz-Cartelle, a U.S.-based physician, coincides with the transition of the Company focusing mainly on research and development in Israel to the Company increasing its U.S.-based activities, which includes its planned clinical trials for the LIBERTY® Endovascular Robotic Surgical System in the U.S., the regulatory process with the FDA and establishing the commercial foundations to enter

      11/21/23 9:12:03 AM ET
      $MBOT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care